Sciclone Pharmaceuticals, Inc. (SCLN) Misses Q4 EPS by 8c, Guides FY13

April 1, 2013 4:06 PM EDT
Sciclone Pharmaceuticals, Inc. (NASDAQ: SCLN) reported Q4 EPS of $0.04, $0.08 worse than the analyst estimate of $0.12. Revenue for the quarter came in at $33.1 million versus the consensus estimate of $35.3 million.

Sciclone Pharmaceuticals, Inc. sees FY2013 EPS of $0.66-0.72, versus the consensus of $0.65. Sees FY revs of $150 to $155 million vs $153.07 expected.

For earnings history and earnings-related data on Sciclone Pharmaceuticals, Inc. (SCLN) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings